Artur Kaul

TL;DR: A series of further chimeric genomes allowing production of infectious genotype (GT) 1a, 1b, 2a, and 3a particles are created, suggesting that determinants within the structural proteins govern kinetic and efficiency of virus assembly and release and an E1-specific antiserum capable of neutralizing infectivity of all HCV chimeras is described.

TL;DR: Analysis suggests that the direct activation of a lipid kinase by HCV NS5A contributes critically to the integrity of the membranous viral replication complex.

TL;DR: The data show that the mode of virus entry is conserved between these isolates and involves CD81 as a key receptor for pH-dependent virus entry and that interactions of HCV with cell surface-resident glycosaminoglycans aid in efficient infection of Huh7 cells and that CD81 acts during a postattachment step.

TL;DR: It is suggested that Huh-7 cells lack host cell factors that are important for virus particle assembly and/or release, and selectable full-length HCV genomes that amplify to high levels in the human hepatoma cell line Huh- 7 are generated.

TL;DR: DBIO‐025, a compound that is also endowed with potent anti‐HIV activity and is well tolerated in animals and humans, may form an attractive new option for the therapy of HCV infections, particularly in HCV/HIV co‐infected patients.